Literature DB >> 21741351

KSHV regulation of fibulin-2 in Kaposi's sarcoma: implications for tumorigenesis.

Donald J Alcendor1, Susan Knobel, Prashant Desai, Wen Qui Zhu, Gary S Hayward.   

Abstract

Kaposi's sarcoma is an angioproliferative tumor caused by Kaposi's sarcoma-associated herpesvirus (KSHV) infection of vascular endothelial cells. Fibulins, proteins that associate with extracellular matrix (ECM) proteins, may have both tumor-suppressive and oncogenic activities. We found that the expression of fibulin-2 protein and mRNA were decreased 50-fold and 26-fold, respectively, in 10-day KSHV-infected dermal microvascular endothelial cells (DMVEC). Using quantitative RT-PCR, we found a fivefold and 25-fold decrease of fibulin-2 extracellular matrix binding partners, fibronectin and tropoelastin, respectively. Time-course transcriptional analyses over 10 days showed that in addition to that of fibulin-2, expression of fibulins 3 and 5 was decreased in KSHV-infected DMVEC, fibulins 1C/1D were increased, and fibulins 4, 6, and 7 were unchanged. KSHV latency-associated nuclear antigen (LANA) transcription levels rose consistently over the same period. Addition of recombinant fibulin-3 or -5 for 48 hours to 10-day KSHV-infected cells caused a suppression of KSHV-induced vascular endothelial growth factor (VEGF) protein and mRNA levels. Recombinant fibulin-3 also significantly reduced VEGF receptor 3 expression. In pleural effusion lymphoma cell lines that express variable levels of KSHV lytic replication, we observed no detectable fibulin-2 or -5 expression. Finally, fibulin-2 expression was decreased in tissue microarrays from KSHV-infected, LANA-positive patient cells as compared to that in patient nontumor controls. Understanding the interactions between KSHV and the fibulins may lead to the development of novel therapies for treatment of Kaposi's sarcoma.
Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21741351      PMCID: PMC3157165          DOI: 10.1016/j.ajpath.2011.05.024

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  40 in total

1.  A new primary effusion lymphoma-derived cell line yields a highly infectious Kaposi's sarcoma herpesvirus-containing supernatant.

Authors:  J S Cannon; D Ciufo; A L Hawkins; C A Griffin; M J Borowitz; G S Hayward; R F Ambinder
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

Review 2.  Kaposi's sarcoma in South Africa.

Authors:  F Sitas; R Newton
Journal:  J Natl Cancer Inst Monogr       Date:  2001

3.  Human fibulin-4: analysis of its biosynthetic processing and mRNA expression in normal and tumour tissues.

Authors:  W M Gallagher; L M Greene; M P Ryan; V Sierra; A Berger; P Laurent-Puig; E Conseiller
Journal:  FEBS Lett       Date:  2001-01-26       Impact factor: 4.124

4.  Ultraviolet radiation increases tropoelastin mRNA expression in the epidermis of human skin in vivo.

Authors:  J Y Seo; S H Lee; C S Youn; H R Choi; G E Rhie; K H Cho; K H Kim; K C Park; H C Eun; J H Chung
Journal:  J Invest Dermatol       Date:  2001-06       Impact factor: 8.551

5.  Levels of the bcl-2 protein, fibronectin and alpha(5)beta(1) fibronectin receptor in HIV-1-infected patients with Kaposi's sarcoma.

Authors:  D Torre; C Zeroli; R Martegani; A Pugliese; C Basilico; F Speranza
Journal:  Microbes Infect       Date:  2000-12       Impact factor: 2.700

Review 6.  Phenotypic characteristics of Kaposi's sarcoma tumour cells derived from patch-, plaque- and nodular-stage lesions: analysis of cell cultures isolated from AIDS and non-AIDS patients and review of the literature.

Authors:  T Simonart; P Hermans; L Schandene; J P Van Vooren
Journal:  Br J Dermatol       Date:  2000-09       Impact factor: 9.302

Review 7.  Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8): epidemiology and pathogenesis.

Authors:  T F Schulz
Journal:  J Antimicrob Chemother       Date:  2000-04       Impact factor: 5.790

8.  Estrogen induction and overexpression of fibulin-1C mRNA in ovarian cancer cells.

Authors:  Frederic Moll; Dionyssios Katsaros; Gwendal Lazennec; Nicolas Hellio; Pascal Roger; Pierre-Ludovic Giacalone; Dany Chalbos; Thierry Maudelonde; Henri Rochefort; Pascal Pujol
Journal:  Oncogene       Date:  2002-02-07       Impact factor: 9.867

9.  The proteoglycans aggrecan and Versican form networks with fibulin-2 through their lectin domain binding.

Authors:  A I Olin; M Mörgelin; T Sasaki; R Timpl; D Heinegård; A Aspberg
Journal:  J Biol Chem       Date:  2001-01-12       Impact factor: 5.157

10.  DANCE/fibulin-5 promotes elastic fiber formation in a tropoelastin isoform-dependent manner.

Authors:  Risa Nonaka; Satoshi Onoue; Hiroshi Wachi; Fumiaki Sato; Zsolt Urban; Barry C Starcher; Yoshiyuki Seyama
Journal:  Clin Biochem       Date:  2009-01-08       Impact factor: 3.281

View more
  15 in total

1.  The expression level of fibulin-2 in the circulating RNA (ctRNA) of epithelial tumor cells of peripheral blood and tumor tissue of patients with metastatic lung cancer.

Authors:  Mukaddes Avsar; Makbule Tambas; Zubeyde Yalniz; Demet Akdeniz; Seref Bugra Tuncer; Seda Kilic; Ozge Sukruoglu Erdogan; Rumeysa Ciftci; Nergiz Dagoglu; Sezai Vatansever; Hulya Yazici
Journal:  Mol Biol Rep       Date:  2019-05-08       Impact factor: 2.316

2.  An In Vitro Model for Studying Cellular Transformation by Kaposi Sarcoma Herpesvirus.

Authors:  Shane C McAllister; Ryan L Hanson; Kyleen N Grissom; Sara Botto; Ashlee V Moses
Journal:  J Vis Exp       Date:  2017-08-25       Impact factor: 1.355

3.  KSHV Down-regulates Tropoelastin in Both an in-vitro and in-vivo Kaposi's Sarcoma Model.

Authors:  Donald J Alcendor
Journal:  J Oncobiomarkers       Date:  2015

4.  Fibulin 2, a tyrosine O-sulfated protein, is up-regulated following retinal detachment.

Authors:  Yogita Kanan; Daniel Brobst; Zongchao Han; Muna I Naash; Muayyad R Al-Ubaidi
Journal:  J Biol Chem       Date:  2014-04-01       Impact factor: 5.157

5.  Site-specific association with host and viral chromatin by Kaposi's sarcoma-associated herpesvirus LANA and its reversal during lytic reactivation.

Authors:  Alexandre Mercier; Carolina Arias; Alexis S Madrid; Meghan M Holdorf; Don Ganem
Journal:  J Virol       Date:  2014-04-02       Impact factor: 5.103

Review 6.  Role of Fibulins in Embryonic Stage Development and Their Involvement in Various Diseases.

Authors:  Deviyani Mahajan; Sudhakar Kancharla; Prachetha Kolli; Amarish Kumar Sharma; Sanjeev Singh; Sudarshan Kumar; Ashok Kumar Mohanty; Manoj Kumar Jena
Journal:  Biomolecules       Date:  2021-05-02

7.  Fibulin-2 is a driver of malignant progression in lung adenocarcinoma.

Authors:  Brandi N Baird; Mark J Schliekelman; Young-Ho Ahn; Yulong Chen; Jonathon D Roybal; Bartley J Gill; Dhruva K Mishra; Baruch Erez; Michael O'Reilly; Yanan Yang; Mayuri Patel; Xin Liu; Nishan Thilaganathan; Irina V Larina; Mary E Dickinson; Jennifer L West; Don L Gibbons; Diane D Liu; Min P Kim; John M Hicks; Ignacio I Wistuba; Samir M Hanash; Jonathan M Kurie
Journal:  PLoS One       Date:  2013-06-10       Impact factor: 3.240

8.  Regulation of fibulin-2 gene expression by integrin α3β1 contributes to the invasive phenotype of transformed keratinocytes.

Authors:  Dara S Missan; Sridar V Chittur; C Michael DiPersio
Journal:  J Invest Dermatol       Date:  2014-04-02       Impact factor: 8.551

9.  CD147 and downstream ADAMTSs promote the tumorigenicity of Kaposi's sarcoma-associated herpesvirus infected endothelial cells.

Authors:  Lu Dai; Jimena Trillo-Tinoco; Yihan Chen; Karlie Bonstaff; Luis Del Valle; Chris Parsons; Augusto C Ochoa; Jovanny Zabaleta; Bryan P Toole; Zhiqiang Qin
Journal:  Oncotarget       Date:  2016-01-26

10.  KS-Detect - Validation of Solar Thermal PCR for the Diagnosis of Kaposi's Sarcoma Using Pseudo-Biopsy Samples.

Authors:  Ryan Snodgrass; Andrea Gardner; Li Jiang; Cheng Fu; Ethel Cesarman; David Erickson
Journal:  PLoS One       Date:  2016-01-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.